

Saskia J A M Santeagoets

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3771802/publications.pdf>

Version: 2024-02-01

32
papers

1,684
citations

393982

19
h-index

676716

22
g-index

33
all docs

33
docs citations

33
times ranked

2935
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>NKG2A</scp> is a late immune checkpoint on <scp>CD8</scp> T cells and marks repeated stimulation and cell division. International Journal of Cancer, 2022, 150, 688-704.	2.3	22
2	CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. , 2022, 10, e003995.		16
3	Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. , 2022, 10, e004346.		15
4	Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S. , 2022, 10, e003591.		13
5	Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. , 2021, 9, e003671.		15
6	35â€...Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells. , 2021, 9, A41-A41.		0
7	CD163⁺cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. , 2020, 8, e001053.		26
8	CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer. Cancer Immunology Research, 2020, 8, 1311-1321.	1.6	84
9	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 545385.	1.3	14
10	Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. , 2020, 8, e000166.		17
11	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. Oncotarget, 2020, 11, 2092-2105.	0.8	64
12	High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. , 2019, 7, 236.		22
13	Autologous tumor cell vaccination combined with systemic CpG-B and IFN-Î± promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Cancer Immunology, Immunotherapy, 2019, 68, 1025-1035.	2.0	13
14	The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. Clinical Cancer Research, 2019, 25, 240-252.	3.2	45
15	Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. , 2019, 7, 10.		66
16	Intratumoral HPV16-Specific T Cells Constitute a Type Iâ€“Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer. Clinical Cancer Research, 2018, 24, 634-647.	3.2	128
17	NKG2A Blockade Potentiates CD8ÂˆT Cell Immunity Induced by Cancer Vaccines. Cell, 2018, 175, 1744-1755.e15.	13.5	241
18	EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer. PLoS ONE, 2018, 13, e0203402.	1.1	22

#	ARTICLE	IF	CITATIONS
19	A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1505-1518.	2.0	62
20	Immunological effects of everolimus in patients with metastatic renal cell cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2017, 30, 341-352.	1.0	21
21	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. <i>Clinical Immunology</i> , 2016, 168, 47-54.	1.4	21
22	Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. <i>Science Translational Medicine</i> , 2016, 8, 334ra52.	5.8	164
23	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	0.8	58
24	IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. <i>Journal of Translational Medicine</i> , 2013, 11, 37.	1.8	70
25	T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 245-256.	2.0	79
26	Allogeneic dendritic cell (DC) vaccination as an "off the shelf" treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3029-3029.	0.8	0
27	Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1364-1373.	1.5	73
28	Transcriptional profiling of human skin-resident Langerhans cells and CD1a+dermal dendritic cells: differential activation states suggest distinct functions. <i>Journal of Leukocyte Biology</i> , 2008, 84, 143-151.	1.5	41
29	Inducing Antitumor T Cell Immunity: Comparative Functional Analysis of Interstitial Versus Langerhans Dendritic Cells in a Human Cell Line Model. <i>Journal of Immunology</i> , 2008, 180, 4540-4549.	0.4	43
30	Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542.	3.2	114
31	In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1480-1490.	2.0	54
32	A CD34+human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+Langerhans cell precursor. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1337-1344.	1.5	61